Abeona Therapeutics (ABEO) Reports Worldwide Exclusive Licenses with REGENXBIO (RGNX) for Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
Tweet Send to a Friend
Abeona Therapeutics Inc.(NASDAQ: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
